Outcomes | Illustrative comparative risks* (95 % CI) | Relative effect (95 % CI) | No of Participants (studies) | Quality of the evidence (GRADE) | |
---|---|---|---|---|---|
Assumed risk | Corresponding risk | ||||
AZT or d4T - containing combination antiretroviral regimens | ABC -containing combination antiretroviral regimens | ||||
Virologic suppression - Lopinavir/ ritonavir based (VL < 50 copies/ml) | 516 per 1000 | 408 per 1000 | RR 0.79 | 2165 | ⊕ ⊕ ⊝⊝ |
Follow-up: mean 48 weeks | (346–475) | (0.67–0.92) | (1 study) | low | |
Virologic failure | 211 per 1000 | 213 per 1000 | RR 1.01 | 557 | ⊕ ⊕ ⊝⊝ |
Follow-up: mean 24 months | (154–294) | (0.73–1.39) | (1 study) | low | |
Death | 35 per 1000 | 25 per 1000 | RR 0.72 | 557 | ⊕ ⊕ ⊝⊝ |
Follow-up: mean 24 months | (9–67) | (0.27–1.92) | (1 study) | low |